LISATA THERAPEUTICS, INC. (LSTA) Form 8-K — Oct 14, 2026
Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors effective October 13, 2026, expanding the Board from seven to eight members. Farrow will also serve on the Audit Committee and was determined independent under Nasdaq listing rules. Farrow is currently CFO and Chief Strategy Officer of Tarsus Pharmaceuticals and previously led Global Blood Therapeutics through its acquisition by Pfizer, along with CFO roles at ZS Pharma and Hyperion Therapeutics.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.